224 related articles for article (PubMed ID: 23656755)
21. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data.
Łastowska M; Viprey V; Santibanez-Koref M; Wappler I; Peters H; Cullinane C; Roberts P; Hall AG; Tweddle DA; Pearson AD; Lewis I; Burchill SA; Jackson MS
Oncogene; 2007 Nov; 26(53):7432-44. PubMed ID: 17533364
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas.
Fieuw A; Kumps C; Schramm A; Pattyn F; Menten B; Antonacci F; Sudmant P; Schulte JH; Van Roy N; Vergult S; Buckley PG; De Paepe A; Noguera R; Versteeg R; Stallings R; Eggert A; Vandesompele J; De Preter K; Speleman F
Int J Cancer; 2012 Jun; 130(11):2599-606. PubMed ID: 21796619
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification.
Asgharzadeh S; Pique-Regi R; Sposto R; Wang H; Yang Y; Shimada H; Matthay K; Buckley J; Ortega A; Seeger RC
J Natl Cancer Inst; 2006 Sep; 98(17):1193-203. PubMed ID: 16954472
[TBL] [Abstract][Full Text] [Related]
24. High-resolution analysis of chromosomal breakpoints and genomic instability identifies PTPRD as a candidate tumor suppressor gene in neuroblastoma.
Stallings RL; Nair P; Maris JM; Catchpoole D; McDermott M; O'Meara A; Breatnach F
Cancer Res; 2006 Apr; 66(7):3673-80. PubMed ID: 16585193
[TBL] [Abstract][Full Text] [Related]
25. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology Group.
Campbell K; Gastier-Foster JM; Mann M; Naranjo AH; Van Ryn C; Bagatell R; Matthay KK; London WB; Irwin MS; Shimada H; Granger MM; Hogarty MD; Park JR; DuBois SG
Cancer; 2017 Nov; 123(21):4224-4235. PubMed ID: 28696504
[TBL] [Abstract][Full Text] [Related]
26. Gene signatures associated with genomic aberrations predict prognosis in neuroblastoma.
He X; Qin C; Zhao Y; Zou L; Zhao H; Cheng C
Cancer Commun (Lond); 2020 Mar; 40(2-3):105-118. PubMed ID: 32237073
[TBL] [Abstract][Full Text] [Related]
27. High genomic instability predicts survival in metastatic high-risk neuroblastoma.
Stigliani S; Coco S; Moretti S; Oberthuer A; Fischer M; Theissen J; Gallo F; Garavent A; Berthold F; Bonassi S; Tonini GP; Scaruffi P
Neoplasia; 2012 Sep; 14(9):823-32. PubMed ID: 23019414
[TBL] [Abstract][Full Text] [Related]
28. Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma.
Rasmuson A; Segerström L; Nethander M; Finnman J; Elfman LH; Javanmardi N; Nilsson S; Johnsen JI; Martinsson T; Kogner P
PLoS One; 2012; 7(12):e51297. PubMed ID: 23284678
[TBL] [Abstract][Full Text] [Related]
29. Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q.
Simon T; Spitz R; Hero B; Berthold F; Faldum A
Cancer Lett; 2006 Jun; 237(2):215-22. PubMed ID: 16019135
[TBL] [Abstract][Full Text] [Related]
30. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
Wang M; Zhou C; Cai R; Li Y; Gong L
Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
[TBL] [Abstract][Full Text] [Related]
31. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.
Depuydt P; Boeva V; Hocking TD; Cannoodt R; Ambros IM; Ambros PF; Asgharzadeh S; Attiyeh EF; Combaret V; Defferrari R; Fischer M; Hero B; Hogarty MD; Irwin MS; Koster J; Kreissman S; Ladenstein R; Lapouble E; Laureys G; London WB; Mazzocco K; Nakagawara A; Noguera R; Ohira M; Park JR; Pötschger U; Theissen J; Tonini GP; Valteau-Couanet D; Varesio L; Versteeg R; Speleman F; Maris JM; Schleiermacher G; De Preter K
J Natl Cancer Inst; 2018 Oct; 110(10):1084-1093. PubMed ID: 29514301
[TBL] [Abstract][Full Text] [Related]
32. Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q.
McArdle L; McDermott M; Purcell R; Grehan D; O'Meara A; Breatnach F; Catchpoole D; Culhane AC; Jeffery I; Gallagher WM; Stallings RL
Carcinogenesis; 2004 Sep; 25(9):1599-609. PubMed ID: 15090470
[TBL] [Abstract][Full Text] [Related]
33. Chromosome 1p and 11q deletions and outcome in neuroblastoma.
Attiyeh EF; London WB; Mossé YP; Wang Q; Winter C; Khazi D; McGrady PW; Seeger RC; Look AT; Shimada H; Brodeur GM; Cohn SL; Matthay KK; Maris JM;
N Engl J Med; 2005 Nov; 353(21):2243-53. PubMed ID: 16306521
[TBL] [Abstract][Full Text] [Related]
34. Risk estimation of neuroblastoma patients using molecular markers.
Fischer M; Spitz R; Oberthür A; Westermann F; Berthold F
Klin Padiatr; 2008; 220(3):137-46. PubMed ID: 18478485
[TBL] [Abstract][Full Text] [Related]
35. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas.
Guo C; White PS; Weiss MJ; Hogarty MD; Thompson PM; Stram DO; Gerbing R; Matthay KK; Seeger RC; Brodeur GM; Maris JM
Oncogene; 1999 Sep; 18(35):4948-57. PubMed ID: 10490829
[TBL] [Abstract][Full Text] [Related]
36. Clinical characteristics and outcome of patients with neuroblastoma presenting genomic amplification of loci other than MYCN.
Guimier A; Ferrand S; Pierron G; Couturier J; Janoueix-Lerosey I; Combaret V; Mosseri V; Thebaud E; Gambart M; Plantaz D; Marabelle A; Coze C; Rialland X; Fasola S; Lapouble E; Fréneaux P; Peuchmaur M; Michon J; Delattre O; Schleiermacher G
PLoS One; 2014; 9(7):e101990. PubMed ID: 25013904
[TBL] [Abstract][Full Text] [Related]
37. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
Guo C; White PS; Hogarty MD; Brodeur GM; Gerbing R; Stram DO; Maris JM
Med Pediatr Oncol; 2000 Dec; 35(6):544-6. PubMed ID: 11107113
[TBL] [Abstract][Full Text] [Related]
38. Chromosome imbalances and alterations of AURKA and MYCN genes in children with neuroblastoma.
Inandiklioğlu N; Yilmaz S; Demirhan O; Erdoğan S; Tanyeli A
Asian Pac J Cancer Prev; 2012; 13(11):5391-7. PubMed ID: 23317189
[TBL] [Abstract][Full Text] [Related]
39. Neuroblastomas with chromosome 11q loss and single copy MYCN comprise a biologically distinct group of tumours with adverse prognosis.
Luttikhuis ME; Powell JE; Rees SA; Genus T; Chughtai S; Ramani P; Mann JR; McConville CM
Br J Cancer; 2001 Aug; 85(4):531-7. PubMed ID: 11506492
[TBL] [Abstract][Full Text] [Related]
40. Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma.
Ooi WF; Re A; Sidarovich V; Canella V; Arseni N; Adami V; Guarguaglini G; Giubettini M; Scaruffi P; Stigliani S; Lavia P; Tonini GP; Quattrone A
Genes Chromosomes Cancer; 2012 Jun; 51(6):545-56. PubMed ID: 22337647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
